304 related articles for article (PubMed ID: 29103990)
41. Immunoproteomic approach to elucidating the pathogenesis of cryptococcosis caused by Cryptococcus gattii.
Jobbins SE; Hill CJ; D'Souza-Basseal JM; Padula MP; Herbert BR; Krockenberger MB
J Proteome Res; 2010 Aug; 9(8):3832-41. PubMed ID: 20545298
[TBL] [Abstract][Full Text] [Related]
42. A cryptococcal capsular polysaccharide mimotope prolongs the survival of mice with Cryptococcus neoformans infection.
Fleuridor R; Lees A; Pirofski L
J Immunol; 2001 Jan; 166(2):1087-96. PubMed ID: 11145689
[TBL] [Abstract][Full Text] [Related]
43. Influenza A Virus as a Predisposing Factor for Cryptococcosis.
Oliveira LVN; Costa MC; Magalhães TFF; Bastos RW; Santos PC; Carneiro HCS; Ribeiro NQ; Ferreira GF; Ribeiro LS; Gonçalves APF; Fagundes CT; Pascoal-Xavier MA; Djordjevic JT; Sorrell TC; Souza DG; Machado AMV; Santos DA
Front Cell Infect Microbiol; 2017; 7():419. PubMed ID: 29018774
[TBL] [Abstract][Full Text] [Related]
44. Pulmonary Iron Limitation Induced by Exogenous Type I IFN Protects Mice from Cryptococcus gattii Independently of T Cells.
Davis MJ; Moyer S; Hoke ES; Sionov E; Mayer-Barber KD; Barber DL; Cai H; Jenkins L; Walter PJ; Chang YC; Kwon-Chung KJ
mBio; 2019 Jun; 10(3):. PubMed ID: 31213551
[No Abstract] [Full Text] [Related]
45. Dendritic cells in the induction of protective and nonprotective anticryptococcal cell-mediated immune responses.
Bauman SK; Nichols KL; Murphy JW
J Immunol; 2000 Jul; 165(1):158-67. PubMed ID: 10861048
[TBL] [Abstract][Full Text] [Related]
46. A murine model of Cryptococcus gattii meningoencephalitis.
Thompson GR; Wiederhold NP; Najvar LK; Bocanegra R; Kirkpatrick WR; Graybill JR; Patterson TF
J Antimicrob Chemother; 2012 Jun; 67(6):1432-8. PubMed ID: 22378683
[TBL] [Abstract][Full Text] [Related]
47. Spatial Quantification of the Population Exposed to Cryptococcus neoformans and Cryptococcus gattii Species Complexes in Europe: Estimating the Immunocompetent and HIV/AIDS Patients Under Risk.
Alaniz AJ; Carvajal JG; Carvajal MA; Cogliati M; Vergara PM
Risk Anal; 2020 Mar; 40(3):524-533. PubMed ID: 31578757
[TBL] [Abstract][Full Text] [Related]
48. Promising whole-cell vaccines against cryptococcosis.
Ueno K; Tsuge S; Shimizu K; Miyazaki Y
Microbiol Immunol; 2023 May; 67(5):211-223. PubMed ID: 36786396
[TBL] [Abstract][Full Text] [Related]
49. Mortality due to Cryptococcus neoformans and Cryptococcus gattii in low-income settings: an autopsy study.
Hurtado JC; Castillo P; Fernandes F; Navarro M; Lovane L; Casas I; Quintó L; Marco F; Jordao D; Ismail MR; Lorenzoni C; Martinez-Palhares AE; Ferreira L; Lacerda M; Monteiro W; Sanz A; Letang E; Marimon L; Jesri S; Cossa A; Mandomando I; Vila J; Bassat Q; Ordi J; Menéndez C; Carrilho C; Martínez MJ
Sci Rep; 2019 May; 9(1):7493. PubMed ID: 31097746
[TBL] [Abstract][Full Text] [Related]
50. [Cryptococcosis].
Kakeya H; Kohno S
Med Mycol J; 2011; 52(3):183-91. PubMed ID: 21891979
[No Abstract] [Full Text] [Related]
51. Molecular characterization of a mannoprotein with homology to chitin deacetylases that stimulates T cell responses to Cryptococcus neoformans.
Levitz SM; Nong S; Mansour MK; Huang C; Specht CA
Proc Natl Acad Sci U S A; 2001 Aug; 98(18):10422-7. PubMed ID: 11504924
[TBL] [Abstract][Full Text] [Related]
52. Heat killed cells of Cryptococcus neoformans var. grubii induces protective immunity in rats: immunological and histopathological parameters.
Baronetti JL; Chiapello LS; Aoki MP; Gea S; Masih DT
Med Mycol; 2006 Sep; 44(6):493-504. PubMed ID: 16966166
[TBL] [Abstract][Full Text] [Related]
53. Molecular typing, in vitro susceptibility and virulence of Cryptococcus neoformans/Cryptococcus gattii species complex clinical isolates from south-eastern Brazil.
Grizante Barião PH; Tonani L; Cocio TA; Martinez R; Nascimento É; von Zeska Kress MR
Mycoses; 2020 Dec; 63(12):1341-1351. PubMed ID: 32869413
[TBL] [Abstract][Full Text] [Related]
54. Hybrids and hybridization in the Cryptococcus neoformans and Cryptococcus gattii species complexes.
Samarasinghe H; Xu J
Infect Genet Evol; 2018 Dec; 66():245-255. PubMed ID: 30342094
[TBL] [Abstract][Full Text] [Related]
55. Immune evasion by
Hester MM; Carlson D; Lodge JK; Levitz SM; Specht CA
Front Immunol; 2024; 15():1356651. PubMed ID: 38469300
[No Abstract] [Full Text] [Related]
56. Pulmonary cryptococcosis.
Brizendine KD; Baddley JW; Pappas PG
Semin Respir Crit Care Med; 2011 Dec; 32(6):727-34. PubMed ID: 22167400
[TBL] [Abstract][Full Text] [Related]
57. Glucosylceramide Administration as a Vaccination Strategy in Mouse Models of Cryptococcosis.
Mor V; Farnoud AM; Singh A; Rella A; Tanno H; Ishii K; Kawakami K; Sato T; Del Poeta M
PLoS One; 2016; 11(4):e0153853. PubMed ID: 27082428
[TBL] [Abstract][Full Text] [Related]
58. Cryptococcus neoformans- and Cryptococcus gattii-specific IgG, IgA and IgM differ among children and adults with and without cryptococcosis from Colombia.
Becerra-Álvarez P; Escandón P; Lizarazo J; Quirós-Gómez Ó; Firacative C
Med Mycol; 2022 Sep; 60(9):. PubMed ID: 36066645
[TBL] [Abstract][Full Text] [Related]
59. Detection of antibodies to phospholipase B in patients infected with Cryptococcus neoformans by enzyme-linked immunosorbent assay (ELISA).
Santangelo RT; Chen SC; Sorrell TC; Wright LC
Med Mycol; 2005 Jun; 43(4):335-41. PubMed ID: 16110779
[TBL] [Abstract][Full Text] [Related]
60. Histopathological study of murine pulmonary cryptococcosis induced by Cryptococcus gattii and Cryptococcus neoformans.
Okubo Y; Wakayama M; Ohno H; Yamamoto S; Tochigi N; Tanabe K; Kaneko Y; Yamagoe S; Umeyama T; Shinozaki M; Nemoto T; Nakayama H; Sasai D; Ishiwatari T; Shimodaira K; Yamamoto Y; Kamei K; Miyazaki Y; Shibuya K
Jpn J Infect Dis; 2013; 66(3):216-21. PubMed ID: 23698482
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
